Kenichi Inoue

15.3k total citations · 4 hit papers
255 papers, 8.6k citations indexed

About

Kenichi Inoue is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kenichi Inoue has authored 255 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Kenichi Inoue's work include Cancer Treatment and Pharmacology (66 papers), Breast Cancer Treatment Studies (55 papers) and HER2/EGFR in Cancer Research (54 papers). Kenichi Inoue is often cited by papers focused on Cancer Treatment and Pharmacology (66 papers), Breast Cancer Treatment Studies (55 papers) and HER2/EGFR in Cancer Research (54 papers). Kenichi Inoue collaborates with scholars based in Japan, United States and Spain. Kenichi Inoue's co-authors include Norikazu Masuda, Hiroji Iwata, Pierfranco Conté, Masato Takahashi, Toshinari Yamashita, Masakazu Toi, Gábor Rubovszky, Zsuzsanna Pápai, Fabrice André and Bella Kaufman and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kenichi Inoue

237 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. profile →
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

2020 371 citations Fabrice André, Dejan Juric et al. profile →

Peers

Kenichi Inoue

ONCOL

PRM

SURGE

Noboru Yamamoto Japan

Ylermi Soini Finland

Xuelei Ma China

Hong Zhao China

Min Yan China

Kōichi Goto Japan

Zhen Chen China

Rui Manuel Reis Brazil

Sang Eun Lee South Korea

Yuan Li China

Noboru Yamamoto Japan

Kenichi Inoue

7.3k ×1.7

ONCOL

5.3k ×1.5

PRM

1.6k ×0.7

3.3k ×1.8

879 ×0.8

SURGE

Citations per year, relative to Kenichi Inoue Kenichi Inoue (= 1×) peers Noboru Yamamoto

Countries citing papers authored by Kenichi Inoue

Since Specialization

Citations

This map shows the geographic impact of Kenichi Inoue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenichi Inoue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenichi Inoue more than expected).

Fields of papers citing papers by Kenichi Inoue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenichi Inoue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenichi Inoue. The network helps show where Kenichi Inoue may publish in the future.

Co-authorship network of co-authors of Kenichi Inoue

This figure shows the co-authorship network connecting the top 25 collaborators of Kenichi Inoue. A scholar is included among the top collaborators of Kenichi Inoue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenichi Inoue. Kenichi Inoue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kamikubo, Yuichi, Koichi Yamaguchi, Kenichi Inoue, et al.. (2025). Tissue Factor Pathway–Driven Initial Thrombin Generation is Associated with Hypercoagulability in Obesity. Thrombosis and Haemostasis. 126(1). 49–59.

Kogawa, Takahiro, Toshinari Yamashita, Takanori Ishida, et al.. (2024). Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). 3103–3103. 1 indexed citations

Im, Seock‐Ah, Javier Cortés, David W. Cescon, et al.. (2024). Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. npj Breast Cancer. 10(1). 79–79. 5 indexed citations

Grischke, Eva‐Maria, Antonio Llombart‐Cussac, Masakazu Toi, et al.. (2023). Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20(2). e5–e6. 1 indexed citations

Inoue, Kenichi, Norikazu Masuda, Hiroji Iwata, et al.. (2021). Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 28(5). 1038–1050. 15 indexed citations

Vollmann, Manja, Ayako Matsuda, Judith R. Kroep, et al.. (2020). <p>Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study</p>. Patient Related Outcome Measures. Volume 11. 67–71. 8 indexed citations

Hayashi, Yuji, Hiroyuki Takei, Tsuyoshi Saito, et al.. (2020). Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer. Journal of Nippon Medical School. 88(4). 354–360. 1 indexed citations

André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940. 1565 indexed citations breakdown →

Iwata, Hiroji, Norikazu Masuda, Sung‐Bae Kim, et al.. (2019). Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer. Future Oncology. 15(21). 2489–2501. 7 indexed citations

10.

Kurozumi, Sasagu, Kenichi Inoue, Hiroshi Matsumoto, et al.. (2019). Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports. 9(1). 16662–16662. 39 indexed citations

11.

Xu, Binghe, Sung‐Bae Kim, Kenichi Inoue, et al.. (2019). Neratinib-Based Therapy in Patients with Metastatic HER2-Positive Breast Cancer from Asia. Future Oncology. 15(28). 3243–3253. 3 indexed citations

12.

Kurozumi, Sasagu, Yuri Yamaguchi, Hiroshi Matsumoto, et al.. (2018). Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. Medical Molecular Morphology. 52(2). 90–98. 5 indexed citations

13.

Watanabe, Toru, Masaru Kuranami, Kenichi Inoue, et al.. (2017). Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 123(5). 759–768. 28 indexed citations

14.

Kloot, Willem A. van der, Yuka Uchida, Kenichi Inoue, et al.. (2016). The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer.. PubMed. 5(1). 3–3. 15 indexed citations

15.

Kurozumi, Sasagu, Kenichi Inoue, Hiroyuki Takei, et al.. (2015). ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer. 15(1). 622–622. 52 indexed citations

16.

Takada, Mamoru, Toru Higuchi, Hiroyuki Takei, et al.. (2013). Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer. 13(1). 241–241. 22 indexed citations

17.

Takei, Hiroyuki, Masafumi Kurosumi, Takashi Yoshida, et al.. (2009). Positive sentinel lymph node biopsy predicts the number of metastatic axillary nodes of breast cancer. The Breast. 18(4). 244–247. 4 indexed citations

18.

Inoue, Kenichi, et al.. (2006). Interactive Effects of Moisture Content and Bulk Density of Soils and Addition of Dried Swine Feces on Denitrification in Upland Soils. Nihon Dojo Hiryogaku zasshi/Nippon dojō hiryōgaku zasshi. 77(6). 659–665. 1 indexed citations

19.

Inoue, Kenichi, et al.. (1998). A Case of Nephroblastoma in a Cat.. 29(3). 91–99.

20.

Fujita, Tetsuro, Kenichi Inoue, Satoshi Yamamoto, et al.. (1990). A Novel Immunosuppressant, ISP-I, of Isaria sinclairii. Journal of Pharmacobio-Dynamics. 13(3). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact